Home » Topics » Drugs » Immuno-oncology

Immuno-oncology
RSS

Amgen returns epratuzumab rights to Immunomedics

April 15, 2004

Financing at Favrille supports phase II and phase III trials

April 14, 2004

ZymoGenetics cleared to commence phase I study of IL-21

April 7, 2004

Improvement in survival indicated in phase IIb trial of L-BLP-25

April 7, 2004

Promising initial clinical results for HYB-2055 presented in Orlando

April 6, 2004

AMD-3100 enters fifth phase II trial for stem cell transplantation

April 6, 2004

Canvaxin reported to improve survival of patients with early stage melanoma

April 6, 2004

Immunotherapy with antigen presenting cells for metastatic breast and prostate cancer

April 6, 2004

Monoclonal antibody effective against cancer progression in vivo

April 5, 2004

WX-G250 plus IFNalpha-2a reported safe and effective in renal cell carcinoma

April 2, 2004

Popular Stories

Today's news in brief
BioWorld
SCAN is core circuit affected in Parkinson’s disease
BioWorld Science
Parkinson’s disease (PD) is a neurodegenerative disorder that affects movement, and tremor is one of its signatures. But it is a much more wide-ranging disorder,...
TL1A is overexpressed in hidradenitis suppurativa
BioWorld Science
Despite the availability of advanced therapeutic options, about 40%-50% of patients with hidradenitis suppurativa do not achieve significant improvement in...
IL-22 and TL1A, a robust couple for diagnosing hidradenitis suppurativa
BioWorld Science
Hidradenitis suppurativa (HS) is a chronic inflammatory skin disease with strong association with psoriasis and inflammatory bowel disease (IBD). While some...
Inhibiting the NLRP3 inflammasome for cognitive impairment, stroke
BioWorld Science
Vascular cognitive impairment and dementia (VCID) and cerebral small vessel disease are among the leading causes of dementia, where inflammation is known to play...